Tetrahydrocannabivarin (THCV) Research Dashboard
Double-blind human trials
Clinical human trials
What am I missing as a non-subscriber?
To see a full dashboard with study details and filtering, go to our DEMO page.
As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.
CannaKeys has 15 studies associated with Tetrahydrocannabivarin (THCV).
Here is a small sampling of Tetrahydrocannabivarin (THCV) studies by title:
- Beneficial effects of the phytocannabinoid Δ 9-THCV in L-DOPA-induced dyskinesia in Parkinson's disease
- Antioxidant and antimicrobial activity of two standardized extracts from a new Chinese accession of non-psychotropic Cannabis sativa L
- Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders
- Δ8 -Tetrahydrocannabivarin has potent anti-nicotine effects in several rodent models of nicotine dependence
- Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study.
Components of the Tetrahydrocannabivarin (THCV) Research Dashboard
- Top medical conditions associated with Tetrahydrocannabivarin (THCV)
- Proven effects in clinical trials for Tetrahydrocannabivarin (THCV)
- Receptors associated with Tetrahydrocannabivarin (THCV)
- Individual study details for Tetrahydrocannabivarin (THCV)
Ready to become a subscriber? Go to our PRICING page.
Members can filter by the following criteria:
- Study Type
- Organ Systems
- Study Result
- Year of Publication
Overview - Tetrahydrocannabivarin (THCV)
Description of Tetrahydrocannabivarin (THCV)
Δ9-Tetrahydrocannabivarin (THCV) was discovered in 1971. It belongs to the THC group but produces different effects than THC. A lot of attention is given THCV of late due to the observation that it may be able to produce therapeutic effects in obesity related diabetes especially in contrast to the failed approach with Rimonabant, the CB1 inverse agonist used to treat obesity but then pulled from market due to the potential increased of mood disorders.
Tetrahydrocannabivarin (THCV) Properties and Effects
Affects lipid and sugar metabolism, Antipsychotic effects
Tetrahydrocannabivarin (THCV) Receptor Binding
Recent reports suggest THCV is a tissue specific or dose-dependent (high dose) agonist/(low does) antagonist at CB1 receptors. Recent reports suggest THCV is a tissue specific or dose-dependent (high dose) agonist/(low does) antagonist at CB2 receptors. GPR-55 receptors. TRPV receptors. Serotonin receptors (5-HT1A)
Disclaimers: Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own physician or other medical professional. You should not use the information contained herein for diagnosing a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a medical problem, promptly contact your health care provider.
Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.